Compare Permian Resources Corporation Class A Common Stock (PR) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Permian Resources Corporation Class A Common Stock vs Repligen Corporation Common Stock — how do they compare? Permian Resources Corporation Class A Common Stock trades at $24.06 (market cap $20.32B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Permian Resources Corporation Class A Common Stock is the larger of the two by market cap, and Permian Resources Corporation Class A Common Stock pays a 2.6% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Permian Resources Corporation Class A Common Stock for 5 Days and Repligen Corporation Common Stock for 0 Days on average.
| PR | RGEN | |
|---|---|---|
Market Cap | $20.32B | $11.14B |
Volume | 10,979,775 | 1,259,263 |
Sector | Energy | Health |
52-Week High | $24.49 | $194.57 |
52-Week Low | $12.09 | $102.87 |
Typical Hold Time | 5 Days | 0 Days |
Enterprise Value | $23.32B | $11.02B |
Dividend Yield | 2.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Permian Resources (PR) trades at $24.26, up 3.68% on the day and near its 52-week high, with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with $5.07B revenue, 21.52% net income margin, and attractive valuation metrics including a P/E of 15.65 and EV/EBITDA of 5.83. Recent earnings show mixed results with Q2 2026 beating expectations by 59% while Q1 2026 missed estimates.
The outlook remains positive with 90% analyst buy ratings and $27.00 consensus price target representing 11% upside. Key opportunities include disciplined acquisition strategy and raised 2026 guidance, while risks involve oil price volatility and execution of capital spending plans. The stock offers growth potential but requires monitoring of quarterly execution consistency.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Permian Resources Corporation Class A Common Stock
Permian Resources explores for and produces oil and natural gas in the Permian Basin. Its operations are concentrated in the Delaware Basin of West Texas and New Mexico.
Read more on PR →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
